share_log

Virpax Pharmaceuticals | 8-K: Current report

Virpax Pharmaceuticals | 8-K: Current report

Virpax制药 | 8-K:重大事件
美股SEC公告 ·  07/03 17:06

Moomoo AI 已提取核心信息

Virpax Pharmaceuticals, Inc. received a notification from Nasdaq on June 28, 2024, indicating that the company's common stock had not met the minimum closing bid price of $1.00 per share over the past 30 consecutive business days, from May 15, 2024, to June 27, 2024. This failure to comply with Nasdaq Listing Rule 5550(a)(2) does not immediately affect the trading of Virpax's common stock, which continues to be listed under the ticker VRPX. The company has been granted a 180-day period, until December 26, 2024, to regain compliance. To achieve this, the closing bid price must be at or above $1.00 for at least ten consecutive business days during this period. Virpax Pharmaceuticals is considering measures, including a potential reverse stock split, to address the compliance issue and maintain its listing on The Nasdaq Capital Market.
Virpax Pharmaceuticals, Inc. received a notification from Nasdaq on June 28, 2024, indicating that the company's common stock had not met the minimum closing bid price of $1.00 per share over the past 30 consecutive business days, from May 15, 2024, to June 27, 2024. This failure to comply with Nasdaq Listing Rule 5550(a)(2) does not immediately affect the trading of Virpax's common stock, which continues to be listed under the ticker VRPX. The company has been granted a 180-day period, until December 26, 2024, to regain compliance. To achieve this, the closing bid price must be at or above $1.00 for at least ten consecutive business days during this period. Virpax Pharmaceuticals is considering measures, including a potential reverse stock split, to address the compliance issue and maintain its listing on The Nasdaq Capital Market.
Virpax Pharmaceuticals,Inc.于2024年6月28日收到了纳斯达克的通知,该公司的普通股从2024年5月15日至2024年6月27日连续30个营业日未达到每股1.00美元的最低收盘竞价价格。这种未能遵守纳斯达克上市规则5550(a)(2)的情况不会立即影响Virpax普通股的交易,该股票将继续在VRPX作为股票代码的情况下上市。公司已获得180天的时间期限,即到2024年12月26日以恢复合规。为达到这个目标,在此期间,收盘竞价价格必须至少连续10个营业日达到或超过1.00美元。Virpax制药正在考虑各种措施,包括潜在的股票拆分以应对合规问题并维持其在纳斯达克资本市场的上市。
Virpax Pharmaceuticals,Inc.于2024年6月28日收到了纳斯达克的通知,该公司的普通股从2024年5月15日至2024年6月27日连续30个营业日未达到每股1.00美元的最低收盘竞价价格。这种未能遵守纳斯达克上市规则5550(a)(2)的情况不会立即影响Virpax普通股的交易,该股票将继续在VRPX作为股票代码的情况下上市。公司已获得180天的时间期限,即到2024年12月26日以恢复合规。为达到这个目标,在此期间,收盘竞价价格必须至少连续10个营业日达到或超过1.00美元。Virpax制药正在考虑各种措施,包括潜在的股票拆分以应对合规问题并维持其在纳斯达克资本市场的上市。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息